AIP Antibody

1. AIP mutation is associated with familial pituitary adenoma syndromes. PMID: 28689311
2. A missense variant in aryl hydrocarbon receptor-interacting protein (AIP) gene and a truncating mutation in multiple endocrine neoplasia I protein (MEN1) gene were both detected in the proband and his father, showing limited co-segregation with phenotype. PMID: 29848728
3. The array was immunoscreened with serum from the patient in dilution 1:2000, and a strong signal on the array was identified as AIPL1, a protein with expression specifically restricted to the retina and the pineal gland. PMID: 26854037
4. Earlier diagnosis of AIP-related acromegaly-gigantism cases enables timely clinical evaluation and treatment, thereby improving outcomes in terms of excessive linear growth and acromegaly comorbidities--{REVIEW} PMID: 28483363
5. Therefore, both functional and structural studies reveal that N-terminus mutations in the AIP gene alter protein behaviour significantly and hence can truly be pathogenic in nature. PMID: 28255869
6. This study of human fibroblasts bearing endogenous heterozygous AIP mutations and transfected pituitary GH3 cells shows that AIP mutations affect the AIP protein level and alter AhR transcriptional activity in a gene- and tissue-dependent manner. PMID: 27080473
7. The expression of PDE4A4 and PDE4A8 in normal pituitary, their increased expression in adenomatous pituitary cells where AIP is meant to participate, and the disruption of the PDE4A4-AIP interaction by AIP mutants may play a role in pituitary tumorigenesis. PMID: 27267386
8. The aryl hydrocarbon receptor interacting protein (AIP) founder mutation R304(*) is frequent in Mid Ulster, resulting in numerous acromegaly/gigantism cases. PMID: 27650164
9. the well-known interaction between AIP and 2 different isoforms of phosphodiesterases (PDEs), PDE2A3 and PDE4A5, is of particular interest. While the interaction with over-expressed AIP does not seem to affect PDE2A3 function, the reported effect on PDE4A5 is, in contrast, reduced enzymatic activity. PMID: 28427099
10. The c.805_825dup allele in AIP, originating from a common ancestor, associates with a severe clinical phenotype of gigantism. PMID: 28634279
11. p.R3O4Q mutation, p.R304* mutation, and IVS3+1G>A mutation found in acromegaly cases PMID: 26815903
12. The prevalence of AIP mutations in young Mexican patients with acromegaly is similar to that of European cohorts. PMID: 27033541
13. Enhanced proteasomal degradation is a novel pathogenic mechanism for AIPmuts, with direct implications for the phenotype in pituitary adenomas. PMID: 27253664
14. Case Report: truncating AIP mutation, p.W279*, in father/daughter presenting with familial isolated pituitary adenoma. PMID: 27838609
15. A modest relationship was found between PPARalpha and AIP expression, both being significantly higher in the presence of pre-operative somatostatin analogues in somatotropinoma patients. PMID: 26872613
16. The prevalence of AIP(mut) in Turkish patients was found to be 1 % in sporadic acromegaly in the present study. PMID: 26021842
17. No digenism with AIP was identified among patients with sporadic pituitary adenomas. PMID: 26792934
18. The aim of this study was to examine mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene PMID: 25938168
19. AIP mutations are associated with pituitary gigantism. PMID: 26187128
20. in a family of a patient with gigantism, identified a new AIP germline mutation (c.685C>T, p.Q229X) predicted to produce a truncated AIP protein, lacking its biological properties due to the disruption of the C-terminus binding sites for both the chaperones and the client proteins of AIP PMID: 24996936
21. a small angle X-ray scattering-derived solution structure of aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) and functional properties of disease-linked AIPL1-proline-rich domain mutants PMID: 26139345
22. traces the current state of knowledge regarding the clinical features of FIPA and the particular genetic, pathologic, and clinical characteristics of pituitary adenomas due to AIP mutations [review] PMID: 25732638
23. The frequency of AIPmut in this registry-based cohort of young patients with acromegaly is lower than previously reported PMID: 25093619
24. The interaction between AIP and IRF7 is enhanced upon virus infection, and AIP potently inhibits IRF7-induced type I IFN (IFN-alpha/beta) production. PMID: 25911105
25. Results provide novel evidence that AIP has an important role in the regulation of cAMP synthesis. PMID: 24662816
26. In T cells, transient binding of CARMA1 and AIP enhanced formation of the CBM complex. Thereby, AIP promoted optimal IKK/NF-kappaB signaling and IL-2 production in response to TCR/CD28 co-stimulation. PMID: 25245034
27. A relatively low prevalence of AIP gene mutations in young patients with apparently sporadic pituitary adenomas presenting to a tertiary pituitary UK centre. PMID: 25184284
28. phenotypic characteristics of familial pituitary adenoma or somatotropinoma due to AIP mutation vary between families or even between individuals within a family PMID: 23743763
29. A report of a Spanish family with familial isolated pituitary adenoma in whom a mutation in the AIP gene previously unreported in a familiar context was identified. PMID: 24078436
30. Our unique case report provides new data for what appears to be a new phenotype for AIP mutation-positive patients: apoplexy and consequently pituitary deficiency (rather than hormone excess). PMID: 24025584
31. Aryl hydrocarbon receptor interacting protein (AIP) and AIP like 1 (AIPL1) are cochaperones of Hsp90 which share 49% sequence identity. Both proteins contain a FKBP-like prolyl peptidyl isomerase domain followed by a tetratricopeptide repeat domain. PMID: 23418749
32. NMR-based structure determination of AIP(2-166) revealed a typical FKBP fold with five antiparallel beta-strands forming a half beta-barrel wrapped around a central alpha-helix, thus permitting AIP to be also named FKBP37.7 according to FKBP nomenclature. PMID: 23418784
33. Data report a FIPA family harbouring an AIP R16H change, supporting the hypothesis that the latter represents a variant of unknown significance. PMID: 22915287
34. Review assesses the current clinical and therapeutic characteristics of more than 200 FIPA families and addresses research findings among AIP mutation-bearing patients in different populations with pituitary adenomas. PMID: 23371967
35. genetic association study in population in Italy: Data suggest that mutation in AIP gene is rarely involved in parathyroid adenomas, but germ-line nature of mutations found suggests that AIP mutation might predispose to primary hyperparathyroidism. PMID: 23633209
36. C-terminal AIP mutations appear to only disrupt client-protein binding to the Calpha-7h, while chaperone binding remains unaffected, suggesting that failure of client-protein interaction with the Calpha-7h is sufficient to predispose to pituitary adenoma. PMID: 23300914
37. Close to 10% of patients with sporadic pituitary macroadenomas were found to have mutations in AIP. PMID: 23321498
38. AIP germline mutations show a low, but non-negligible, prevalence in non-familial acromegaly patients with tumors resistant to treatment with somatostatin analogues PMID: 23038625
39. Data suggest that pituitary tumor suppressor gene AIP (aryl hydrocarbon receptor-interacting protein) is a target gene for miR-107 (microRNA 107); AIP and miR-107 interact and both may play roles in pituitary adenoma tumorigenesis. PMID: 22811466
40. AIP expression in sporadic somatotropinomas without AIP mutations is a predictor of acromegaly control with octreotide LAR treatment independent of SSTR2 expression PMID: 22420004
41. Data show that MEN1 gene is the main target for genetic analysis in Multiple endocrine neoplasia type 1 (MEN1) syndrome, and suggest that in patients without MEN1 gene mutation, CDKN1B or AIP genes should also be tested. PMID: 22026581
42. genetic association studies in French population: Data suggest that mutations in AIP are associated with pituitary adenoma; study confirms very low prevalence of germline AIP mutations in patients with apparently sporadic pituitary adenomas. PMID: 22319033
43. eight exonic SNPs were identified at the AIP locus, including three novel SNPs: T48T, L212L, and V302V PMID: 21512261
44. XAP2 exerts a negative effect on ERalpha transcriptional activity and may thus prevent ERalpha-dependent events. PMID: 21984905
45. pituitary adenomas were diagnosed in 2/21 AIPmut-screened carriers; both had asymptomatic microadenomas PMID: 21753072
46. Loss of heterozygoty at the AIP locus might be a late event in a potential progression from hyperplastic to adenomatous tissue. PMID: 21450940
47. mutated in 41 pediatric somatotropinoma cases (review) PMID: 21546764
48. Data show that the frequency of non-functioning adrenal lesions in acromegaly is not associated with aryl hydrocarbon receptor interacting protein gene mutations. PMID: 20595802
49. Familial isolated pituitary neoplasms is a heterogeneous condition, which may be associated with AIP mutation. PMID: 21340155
50. data provide strong evidence for a new founder effect of the AIPR304X mutation in central Italy and the observed variations in disease severity point out the role of additional genetic or environmental factors in such kindreds. PMID: 20354355

显示更多

收起更多

HGNC: 358

OMIM: 102200

KEGG: hsa:9049

STRING: 9606.ENSP00000279146

UniGene: Hs.412433